Anti-Recombinant-SARS-CoV-2 Nucleocapsid protein antibody [22F9] (STJA0002890)
SPECIFICATIONS
ClonalityMonoclonal
HostHuman
ConjugationUnconjugated
IsotypeIgG1 lambda
ImmunogenRecombinant SARS-CoV-2 Nucleocapsid protein produced by CHO-based proprietary suspension cell line. Nucleocapsid protein SARS-CoV-2
General Information
| Short Description | Human monoclonal anti-Recombinant-SARS-CoV-2 Nucleocapsid protein for use in ELISA and WB in SARS-CoV-2 samples. Datasheet included with dilution recommendations, and related reagents. |
| Applications | ELISA/WB |
| Host | Human |
| Reactivity | SARS-CoV-2 |
| Note | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Product Properties
| Clonality | Monoclonal |
| Clone ID | 22F9 |
| Isotype | IgG1 lambda |
| Conjugation | Unconjugated |
| Purification | Protein A affinity chromatography |
| Dilution Range | ELISA 0.08-0.16 ยตg/ml |
| Formulation | PBS pH 7.4 |
| Storage Instruction | Store at-20 ยฐC to-70 ยฐC long term. Avoid multiple freeze-thaw cycles. |
| Dissociation Constant | < 1.0 x 10-12ย M |
Target Information
| Immunogen | Recombinant SARS-CoV-2 Nucleocapsid protein produced by CHO-based proprietary suspension cell line. Nucleocapsid protein SARS-CoV-2 |
| Specificity | SARS-CoV-2 Nucleocapsid protein |